European ‘NAFLD Preparedness Index’ — Is Europe ready to meet the challenge of fatty liver disease?

[1]  P. Bossuyt,et al.  Prognostic accuracy of FIB‐4, NAFLD fibrosis score and APRI for NAFLD‐related events: A systematic review , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[2]  J. Lazarus,et al.  The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data , 2020, PloS one.

[3]  J. Lazarus,et al.  Do the most heavily burdened countries have the right policies to eliminate viral hepatitis B and C? , 2020, The lancet. Gastroenterology & hepatology.

[4]  B. Jönsson,et al.  Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study , 2020, JHEP reports : innovation in hepatology.

[5]  A. Mazur,et al.  Ultra-Processed Food Consumption among the Paediatric Population: An Overview and Call to Action from the European Childhood Obesity Group , 2020, Annals of Nutrition and Metabolism.

[6]  F. Tacke,et al.  The socioeconomic aspects of nonalcoholic fatty liver disease: food insecurity as a novel risk factor for steatosis and liver fibrosis. , 2020, Hepatobiliary surgery and nutrition.

[7]  B. Neuschwander‐Tetri.  Therapeutic landscape for NAFLD in 2020. , 2020, Gastroenterology.

[8]  Z. Younossi,et al.  Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD , 2020, Hepatology.

[9]  G. Marchesini,et al.  Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation , 2020, Hepatology.

[10]  F. Tacke,et al.  A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. , 2020, Journal of hepatology.

[11]  Manfred von der Ohe,et al.  Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial , 2019, The Lancet.

[12]  Mohammad Hossein Khosravi,et al.  Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017 , 2019, JAMA oncology.

[13]  P. Tien,et al.  Food Insecurity May Be an Independent Risk Factor Associated with Nonalcoholic Fatty Liver Disease among Low-Income Adults in the United States. , 2019, The Journal of nutrition.

[14]  J. Hodson,et al.  Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study , 2019, Journal of hepatology.

[15]  M. Heikenwalder,et al.  From NASH to HCC: current concepts and future challenges , 2019, Nature Reviews Gastroenterology & Hepatology.

[16]  Elizabeth Morris,et al.  Association of Weight Loss Interventions With Changes in Biomarkers of Nonalcoholic Fatty Liver Disease , 2019, JAMA internal medicine.

[17]  A. Sanyal.  Past, present and future perspectives in nonalcoholic fatty liver disease , 2019, Nature Reviews Gastroenterology & Hepatology.

[18]  S. Dombrowski,et al.  Using the theoretical domains framework to identify barriers and enabling factors to implementation of guidance for the diagnosis and management of nonalcoholic fatty liver disease: a qualitative study , 2019, Translational behavioral medicine.

[19]  M. Plauth,et al.  ESPEN guideline on clinical nutrition in liver disease. , 2019, Clinical nutrition.

[20]  S. Asch,et al.  Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. , 2018, Gastroenterology.

[21]  Reza Ghadimi.  Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017 , 2018, Lancet.

[22]  G. Galea,et al.  Forecasting Future Trends in Obesity across Europe: The Value of Improving Surveillance , 2018, Obesity Facts.

[23]  M. Manns,et al.  Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. , 2018, Journal of hepatology.

[24]  J. Lazarus,et al.  Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. , 2018, Journal of hepatology.

[25]  A. Sanyal.  Putting non-alcoholic fatty liver disease on the radar for primary care physicians: how well are we doing? , 2018, BMC Medicine.

[26]  E. Tsochatzis,et al.  Non-alcoholic fatty liver disease and the interface between primary and secondary care. , 2018, The lancet. Gastroenterology & hepatology.

[27]  D. Levy,et al.  Improved Diet Quality Associates With Reduction in Liver Fat, Particularly in Individuals With High Genetic Risk Scores for Nonalcoholic Fatty Liver Disease. , 2018, Gastroenterology.

[28]  B. Neuschwander‐Tetri,et al.  Mechanisms of NAFLD development and therapeutic strategies , 2018, Nature Medicine.

[29]  M. Kontogianni,et al.  Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial , 2018, British Journal of Nutrition.

[30]  Claude B. Sirlin,et al.  How bariatric surgery affects liver volume and fat density in NAFLD patients , 2018, Surgical Endoscopy.

[31]  C. Monteiro,et al.  Consumption of ultra-processed foods and associated sociodemographic factors in the USA between 2007 and 2012: evidence from a nationally representative cross-sectional study , 2018, BMJ Open.

[32]  K. Irvine,et al.  Underappreciation of non‐alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis , 2018, Internal medicine journal.

[33]  G. Bedogni,et al.  Global epidemiology of non‐alcoholic fatty liver disease/non‐alcoholic steatohepatitis: What we need in the future , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[34]  Michal Rein,et al.  Effect of Distinct Lifestyle Interventions on Mobilization of Fat Storage Pools: CENTRAL Magnetic Resonance Imaging Randomized Controlled Trial , 2017, Circulation.

[35]  M. Ekstedt,et al.  Natural History of NAFLD/NASH , 2017, Current Hepatology Reports.

[36]  Manuel Romero-Gómez,et al.  Treatment of NAFLD with diet, physical activity and exercise. , 2017, Journal of hepatology.

[37]  M. Friedrich.  Global Obesity Epidemic Worsening. , 2017, JAMA.

[38]  Joel E. Oestreich.  UNITED NATIONS DEVELOPMENT PROGRAMME , 2000 .

[39]  B. Hanratty,et al.  Detecting liver disease in primary care: are we ready for change? , 2017, The British journal of general practice : the journal of the Royal College of General Practitioners.

[40]  V. Wong,et al.  Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis , 2017, Hepatology.

[41]  L. Le Marchand,et al.  Diet Quality in Mid-Adulthood Predicts Visceral Adiposity and Liver Fatness in Older Ages: The Multiethnic Cohort Study , 2017, Obesity.

[42]  P. Zimmet.  Diabetes and its drivers: the largest epidemic in human history? , 2017, Clinical Diabetes and Endocrinology.

[43]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[44]  H. Tilg,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. , 2016, Journal of hepatology.

[45]  E. Bjornsson,et al.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.

[46]  S. Friedman,et al.  Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. , 2015, Gastroenterology.

[47]  Aijaz Ahmed,et al.  Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. , 2015, Gastroenterology.

[48]  A. Burt,et al.  Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease , 2022 .

[49]  N. Salkind.  Encyclopedia of Measurement and Statistics , 2006 .

[50]  M. Greenacre,et al.  Multiple Correspondence Analysis and Related Methods , 2006 .

[51]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .

[52]  L. Henry,et al.  NAFLD AND NASH: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018 .

[53]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[54]  S. Jebb,et al.  Foresight. Tackling obesities: future choices. Project report. , 2007 .

[55]  H. Abdi,et al.  Multiple Correspondence Analysis , 2006 .